Breaking barriers in prostate cancer: the mRNA vaccine breakthrough and what comes next

npj Vaccines 2026 Open access

Read full text
Authors: Rayan Rajabi, Somayeh Vafaei, Fatemeh Afrashteh, Roya Ghods, Zahra Madjd
DOI: 10.1038/s41541-025-01358-9
Cited by: 1
References: 176

Abstract

Prostate cancer (PC) treatment is evolving beyond conventional therapies. This review explores mRNA-based vaccines as a promising immunotherapy. We discuss their mechanism of action, advantages in production and safety, and results from early clinical trials (e.g., CV9103/4). Key challenges like antigen selection and the immunosuppressive tumor microenvironment are addressed, alongside advancements in lipid nanoparticle delivery and combinatorial strategies with checkpoint inhibitors to enhance efficacy and usher in personalized PC treatment.

Fields of Study & Subjects

RNA Interference and Gene Delivery Immunotherapy and Immune Responses Prostate Cancer Treatment and Research

Publication details

Journal / source
npj Vaccines
Publisher
Springer Science and Business Media LLC
Volume
11
Issue
1
Pages
36–36
Publication date
7 January 2026
Language
EN